Clinical Research Directory
Browse clinical research sites, groups, and studies.
MRD Monitoring in Lung Cancer After Resection
Sponsor: Guangdong Provincial People's Hospital
Summary
The conception of molecular residual disease (MRD) extending from hematologic tumor to solid tumors. Evidences supporting MRD evaluation for lung cancer by liquid biopsy has gradually accumulated, especially circulating tumor DNA (ctDNA). In this observational study, the investigators prospectively enroll stage I-IIIA non-small cell lung cancer (NSCLC) patients who underwent complete resection. Preoperative blood sample, tumor tissue and dynamic postoperative blood samples are collected continuously for MRD detection. This study aim to explore the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.
Official title: Dynamic Molecular Residual Disease Detection in Stage I-IIIA Non-Small Cell Lung Cancer After Radical Resection
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2021-09-01
Completion Date
2027-12-30
Last Updated
2022-03-17
Healthy Volunteers
No
Conditions
Interventions
MRD detection
The Geneplus OncoMRD lung assay is used to detect the MRD status.
Locations (1)
Guangdong Lung Cancer Institute & Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China